Radiotherapy for Oligometastatic Prostate Cancer
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Prostate Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/6/2019 |
| Start Date: | May 2013 |
| End Date: | January 2020 |
Phase II Stereotactic Body Radiotherapy (SBRT) and Stereotactic Hypofractionated Radiotherapy (SHRT) for Oligometastatic Prostate Cancer
The purpose of this phase II study is to evaluate the outcomes of patients treated with an
investigational radiation regimen using stereotactic radiotherapy for oligometastatic
prostate cancer and to establish efficacy (producing a desired result or effect) and safety
in this setting.
investigational radiation regimen using stereotactic radiotherapy for oligometastatic
prostate cancer and to establish efficacy (producing a desired result or effect) and safety
in this setting.
This study will serve as a component of a larger program investigating the benefits of
stereotactic radiotherapy in patients with metastatic disease.
This particular study will serve as a benchmark analysis.
All patients will receive stereotactic radiotherapy directed at metastatic tumors.
If primary prostate cancer is active and has not previously been treated with radiation
therapy, conventional radiation therapy (6-8 weeks of daily treatment) may be recommended.
The metastatic tumor will be treated at the same time.
Hormone therapy will be recommended for all patients.
Patients will be asked to complete questionnaires at regular intervals.
stereotactic radiotherapy in patients with metastatic disease.
This particular study will serve as a benchmark analysis.
All patients will receive stereotactic radiotherapy directed at metastatic tumors.
If primary prostate cancer is active and has not previously been treated with radiation
therapy, conventional radiation therapy (6-8 weeks of daily treatment) may be recommended.
The metastatic tumor will be treated at the same time.
Hormone therapy will be recommended for all patients.
Patients will be asked to complete questionnaires at regular intervals.
Inclusion Criteria:
- Patients with metastatic cancer of the prostate,
- Patients may have received prior surgery,
- Prior radiation therapy, androgen deprivation therapy (ADT), immunotherapy, bone
metastasis directed therapy, or chemotherapy for prostate cancer.
Exclusion Criteria:
- End-stage heart disease,
- End-stage liver disease,
- End-stage renal disease,
- End stage pulmonary disease
- Current brain or central nervous system metastasis.
We found this trial at
1
site
2015 Jefferson St
Jacksonville, Florida 32206
Jacksonville, Florida 32206
(904) 588-1800
Principal Investigator: Roi Dagan, MD, MS
Phone: 877-686-6009
University of Florida Proton Therapy Institute When the University of Florida Proton Therapy Institute opened...
Click here to add this to my saved trials
